KLRA · TickerCove

KLRAKailera Therapeutics, Inc.Healthcare · Biotechnologyas of 2026-09-16

Horizon

Issued 2026-09-16 at $12.70 · now $12.70 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, KLRA has typically landed between $9.73 and $15.04 — a range of −23.4% to +18.4% from the issuance price $12.70.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.

Actual close
Typical path (median)
Middle 50% of outcomes
90% range

84 overlapping 1 month windows · 2026-04-17 – 2026-08-17 · basis climatology · forecast (batch).

The cone is anchored at the 2026-09-16 issuance close ($12.70) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

52-week range$12.7 · 0% of range

$12.7 low$26 high

Trailing 52 weeks to 2026-09-16 — factual context, not a signal.

Distribution ranges onlyiThis name has too little trading history to publish a calibrated probability, so we show its distribution ranges only — no directional call. Its record is still building.

No directional probability — ranges below.

Distribution · month iiThe price-anchored range: typical move (median), and the p90 downside/upside — 90% of similar periods stayed inside these. Ranges, not a prediction of direction.

−7.9%

typical move · IQR 13.7%

−23.4%worst (p90)+18.4%best (p90)

Insider convictioniOpen-market common-stock purchases by company insiders in the last 90 days (grants and option exercises excluded). Historical tendency, not advice — detail below.

conviction buys

0 open-market sales

Congress disclosuresiRecent disclosed congressional trades for this company. Purchase clusters (≥2 members buying within 90 days) historically preceded a modestly higher forward return (+32 bp/mo in 2022–2026, +45 bp/mo in 2015–2021) — a descriptive tendency, not a forecast input. Detail below.

0 buys · 0 sells · 0 members

cluster tilt persisted, ~halved after 2021

Where KLRA has typically landed a month from the 2026-09-16 close of $12.7 — the range is history, not a prediction.

now $12.7 (+0.0%)
typical $11.7 (-7.9%)
middle 50% $10.83–$12.57
90% range $9.73–$15.04

Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 84 windows spanning 2026-04-17 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.

Start	Return	Max drop	Max rise
3 worst
2026-08-17	−31.4%	−31.4%	+0.1%
2026-08-14	−25.0%	−25.0%	+3.3%
2026-08-12	−25.0%	−25.0%	+0.0%
3 best
2026-05-20	+14.0%	−7.6%	+15.5%
2026-06-05	+12.3%	−4.2%	+20.3%
2026-07-28	+10.2%	−1.2%	+13.4%

84 overlapping windows · 2026-04-17 – 2026-09-16 · not cherry-picked

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Date	Person	Role	Action	Shares @ price	Value	Ownership Δ	vs S&P 1m	vs S&P 6m	Owned after	Filing
2026-04-20	BAIN CAPITAL INVESTORS LLC	tenPercentOwner	Purchase	8,398,438 @ $16.00	$134.4M	+47.0% of holding	−23.8%	not yet — horizon still open	26,255,581	Form 4 · filed same day
2026-04-20	Kaplan Andrew T.	director	Purchase	8,398,438 @ $16.00	$134.4M	+47.0% of holding	−23.8%	not yet — horizon still open	26,255,581	Form 4 · filed same day
2026-04-20	Bain Capital Life Sciences Investors, LLC	tenPercentOwner	Purchase	1,562,500 @ $16.00	$25.0M	+7.4% of holding	−23.8%	not yet — horizon still open	22,583,268	Form 4 · filed same day
2026-04-20	Koppel Adam	director	Purchase	1,562,500 @ $16.00	$25.0M	+7.4% of holding	−23.8%	not yet — horizon still open	22,583,268	Form 4 · filed same day
2026-04-20	RTW INVESTMENTS, LP	director	Purchase	500,000 @ $16.00	$8.0M	+4.9% of holding	−23.8%	not yet — horizon still open	10,776,820	Form 4 · filed 2 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

62 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

Date	Person	Role	Action	Shares	Owned after	Filing
2026-09-07	Nicholson Nur	officer	Award / grant	220,000	220,000	Form 4
2026-07-06	Tregoning Kathleen	director	Award / grant	175,000	175,000	Form 4
2026-06-09	Renaud Ronald C JR	director	Option exercise	38,094	38,094	Form 4
2026-06-09	Renaud Ronald C JR	director	Option exercise	38,094	817,826	Form 4
2026-04-20	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	tenPercentOwner	Conversion	708,814	0	Form 4
2026-04-20	Bain Capital Life Sciences Investors, LLC	tenPercentOwner	Conversion	16,875,000	0	Form 4
2026-04-20	Kaplan Andrew T.	director	Conversion	17,857,143	0	Form 4
2026-04-20	Bain Capital Life Sciences Investors, LLC	tenPercentOwner	Conversion	4,145,768	0	Form 4
2026-04-20	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	tenPercentOwner	Conversion	4,968,789	0	Form 4
2026-04-20	Koppel Adam	director	Conversion	16,875,000	0	Form 4
2026-04-20	Koppel Adam	director	Conversion	4,145,768	0	Form 4
2026-04-20	BAIN CAPITAL INVESTORS LLC	tenPercentOwner	Conversion	17,857,143	0	Form 4
2026-04-20	Koppel Adam	director	Conversion	16,875,000	16,875,000	Form 4
2026-04-20	Koppel Adam	director	Conversion	4,145,768	21,020,768	Form 4
2026-04-20	Kaplan Andrew T.	director	Conversion	17,857,143	17,857,143	Form 4
2026-04-20	Koppel Adam	director	Conversion	16,875,000	16,875,000	Form 4
2026-04-20	Koppel Adam	director	Conversion	4,145,768	21,020,768	Form 4
2026-04-20	BAIN CAPITAL INVESTORS LLC	tenPercentOwner	Conversion	17,857,143	17,857,143	Form 4
2026-04-20	BAIN CAPITAL INVESTORS LLC	tenPercentOwner	Conversion	17,857,143	17,857,143	Form 4
2026-04-20	Bain Capital Life Sciences Investors, LLC	tenPercentOwner	Conversion	16,875,000	16,875,000	Form 4
2026-04-20	BAIN CAPITAL INVESTORS LLC	tenPercentOwner	Conversion	17,857,143	17,857,143	Form 4
2026-04-20	Bain Capital Life Sciences Investors, LLC	tenPercentOwner	Conversion	16,875,000	16,875,000	Form 4
2026-04-20	Bain Capital Life Sciences Investors, LLC	tenPercentOwner	Conversion	4,145,768	21,020,768	Form 4
2026-04-20	Bain Capital Life Sciences Investors, LLC	tenPercentOwner	Conversion	4,145,768	21,020,768	Form 4
2026-04-20	BAIN CAPITAL INVESTORS LLC	tenPercentOwner	Conversion	17,857,143	17,857,143	Form 4
2026-04-20	Bain Capital Life Sciences Investors, LLC	tenPercentOwner	Conversion	16,875,000	16,875,000	Form 4
2026-04-20	Bain Capital Life Sciences Investors, LLC	tenPercentOwner	Conversion	4,145,768	21,020,768	Form 4
2026-04-20	Bain Capital Life Sciences Investors, LLC	tenPercentOwner	Conversion	16,875,000	16,875,000	Form 4
2026-04-20	Bain Capital Life Sciences Investors, LLC	tenPercentOwner	Conversion	4,145,768	21,020,768	Form 4
2026-04-20	Bain Capital Life Sciences Investors, LLC	tenPercentOwner	Conversion	4,145,768	21,020,768	Form 4
2026-04-20	Bain Capital Life Sciences Investors, LLC	tenPercentOwner	Conversion	16,875,000	16,875,000	Form 4
2026-04-20	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	tenPercentOwner	Conversion	9,477,719	9,477,719	Form 4
2026-04-20	BAIN CAPITAL INVESTORS LLC	tenPercentOwner	Conversion	17,857,143	17,857,143	Form 4
2026-04-20	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	tenPercentOwner	Conversion	2,034,133	2,034,133	Form 4
2026-04-20	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	tenPercentOwner	Conversion	9,477,719	9,477,719	Form 4
2026-04-20	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	tenPercentOwner	Conversion	2,034,133	2,034,133	Form 4
2026-04-20	RTW INVESTMENTS, LP	director	Conversion	10,276,820	10,276,820	Form 4
2026-04-20	RTW INVESTMENTS, LP	director	Conversion	8,250,000	0	Form 4
2026-04-20	RTW INVESTMENTS, LP	director	Conversion	2,026,820	0	Form 4
2026-04-20	RTW INVESTMENTS, LP	director	Conversion	10,276,820	10,276,820	Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Resolves in i

28d remaining

2026-09-173% elapsed2026-10-15

Logged immutably 2026-09-17; scored automatically on 2026-10-15 — no edits, ever.

Earnings & context analysis

These panels are being prepared. They are generated by multiple language models, checked, and stored before display — never written live for a page view. Until a model panel has been generated and reviewed for a company, nothing is shown here, honestly, rather than a placeholder.

Calibration i

Every forecast is logged when made and scored when the month is up. The record is shown from the day it starts — young and honest.

How scoring works →

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.